GlaxoSmithKline PLC (GSK.L)
1,750.50GBp
8:43am EDT
8.50p (+0.49%)
1,742.00p
1,744.00p
1,753.00p
1,734.00p
2,258,533
7,632,119
1,753.00p
1,314.00p
GSK.L
About
Overall
| Beta: | 0.44 |
| Market Cap (Mil.): | £85,832.14 |
| Shares Outstanding (Mil.): | 4,927.22 |
| Dividend: | 18.00 |
| Yield (%): | 4.31 |
Financials
| GSK.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 20.61 | 34.93 | 35.13 |
| EPS (TTM): | 0.85 | -- | -- |
| ROI: | 15.87 | 19.47 | 18.83 |
| ROE: | 54.57 | 20.22 | 19.68 |
U.S. government taps GlaxoSmithKline for new antibiotics
LONDON - The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism.
UPDATE 1-Elan strikes $1 bln royalty deal with Theravance
* Elan to acquire newly approved Breo as part of $1 bln deal
FDA approves Glaxo/Theravance drug for COPD lung disease
- The Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both.
UPDATE 3-US FDA approves Glaxo/Theravance drug for COPD lung disease
* Drug will compete with AstraZeneca's Symbicort (Updates with FDA comment, side effects)
JP Morgan, Greenhill advising GSK on sale of soft drinks brands
LONDON, May 2 - JP Morgan and Greenhill have been appointed to advise GlaxoSmithKline on the sale of its soft drinks brands Lucozade and Ribena, which analysts believe will fetch more than 1 billion pounds ($1.6 billion).
Impax, GSK end Parkinson's disease partnership
- Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.
Impax, GSK end Parkinson's disease partnership
April 29 - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.
UPDATE 1-FDA raises concerns on seizure drug of Valeant, Glaxo
April 26 - The U.S. Food and Drug Administration said the an anti-seizure drug developed by Valeant Pharmaceuticals Inc and co-marketed with GlaxoSmithKline Plc may cause eye and skin problems.
BRIEF-GlaxoSmithKline reports submission for UMEC in EU
LONDON, April 26 - GlaxoSmithKline Plc : * Regulatory submission for umeclidinium monotherapy in European union * Regulatory filings for umec monotherapy are imminent in the US and planned in
UPDATE 2-Theravance to split into two listed cos, shares jump
* Oone new company will focus on drugs under deal with GSK
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
